`
ROUND ROCK, Texas, May 6, 2025 — Benuvia Operations, LLC (Benuvia), a global organization for contract development and manufacturing, has announced the signing of an agreement with Trait Biosciences (Trait). The agreement aims to expedite the introduction of novel water-soluble cannabinoids to the market.
As per the agreement, Benuvia will be responsible for scaling up the production of Trait’s primary synthetic tetrahydrocannabidiol (THC) derivatives and ensuring its manufacturability. Furthermore, Benuvia and Trait are considering extending their partnership to include the manufacturing and production of other cannabinoid derivatives.
Terry Novak, CEO of Benuvia, stated that Trait has built a strong reputation within the cannabinoid sector, and they are excited to collaborate with them on this project. He also noted Benuvia’s strong start to the year, driven by increasing demand for early-stage development research, and expressed their ambition to become the preferred partner for companies seeking a comprehensive platform of services spanning from pre-clinical development to commercial launch and supply.
Dr. Hanny Kanafani, president and COO of Trait Biosciences, mentioned that scaling up with Benuvia will help advance their commercial objectives for their water-soluble cannabinoids. It will also enable their customers to integrate their factory-produced water-soluble cannabinoids into their final products. He conveyed his enthusiasm for working with the Benuvia team on this crucial endeavor for Trait.
About Trait Biosciences
Trait Biosciences is a research-driven organization focused on creating truly water-soluble hemp-derived cannabinoids by utilizing biotechnology and chemical synthesis. They also focus on ensuring manufacturability, thus offering customers unique and differentiated ingredients suitable for various consumer products. More details can be found at .
About Benuvia Operations, LLC
Benuvia Operations, LLC is a global Contract Development and Manufacturing Organization (CDMO) aiding pharmaceutical and biotech companies in delivering transformative therapies to patients. They offer comprehensive development and manufacturing services for both Active Pharmaceutical Ingredients (APIs) and finished dosage products. They possess significant expertise in cannabinoids, psychedelics, and other controlled substances. Benuvia manages an 83,000 square foot, state-of-the-art manufacturing facility in Round Rock, Texas, capable of producing Schedule I-V compounds, and providing complete solutions for companies throughout the drug development process—from API synthesis and clinical trial supply to commercial production. Additional information is available at .
Forward Looking Statements
This press release may contain forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Terms such as “anticipate,” “believe,” “could,” “estimate,” “upcoming,” “expect,” “intend,” “may,” “plan,” “redirect,” “project,” “will,” and similar words may indicate forward-looking statements. Our activities involve risks and uncertainties, many of which are beyond our control. Any of these, alone or in combination, could significantly impact our operational results and the reliability of these forward-looking statements, especially when considered alongside the risks and uncertainties detailed in our filings with the Securities and Exchange Commission at . These statements are based on the information we currently have available, and we are not obligated to update them unless required by law.
Contact
KWM Communications
Kellie Walsh
(914) 315-6072
SOURCE Benuvia Operations, LLC